WOBURN, Mass., Feb. 12 AdvanDx announced it has named ElseBeth Trautner, a former Executive Vice President of Dako A/S, as VicePresident of Sales and Marketing. Ms. Trautner will aggressively drive theglobal adoption of AdvanDx's fast, accurate and easy-to-use in vitro moleculardiagnostic products that advance the prevention, diagnosis and treatment ofinfectious pathogens. Ms. Trautner previously managed an organization of morethan 575 employees with annual revenues in excess of $300 million at Dako, aglobal cancer diagnostics company, while successfully restructuring businessoperations in the Asia-Pacific region that led to record sales. Ms. Trautneralso orchestrated the reorganization of 22 sales subsidiaries into 5geographic regions resulting in 15% sales growth and a 9% increase inprofitability during her tenure as Executive Vice President of Global Sales atDako.
"Ms. Trautner is a seasoned executive with proven industry experience whowill drive aggressive growth, market expansion, revenue production andultimately profitability," said Thais T. Johansen, President and CEO ofAdvanDx. "The addition of Ms. Trautner clearly positions AdvanDx to deliverour easy-to-use, life saving molecular diagnostic products worldwide to helptreat patients afflicted with serious infections," Mr. Johansen added.
"I am pleased to join AdvanDx's strong business and scientific managementteam as we make significant inroads into multi-billion dollar markets," saidElse Beth Trautner, Vice President of Sales and Marketing at AdvanDx. "I lookforward to ramping our success in North America while opening up new markets,seizing revenue-generating sales opportunities and further accelerating theadoption of our products in the global marketplace," said Ms. Trautner.
AdvanDx is the world's leading provider of fast, accurate and easy-to-usein vitro molecular diagnostic products that advance the prevention, diagnosisand treatment of infectious pathogens. AdvanDx's products and services enabledramatic improvements in patient care and outcomes while reducing hospitalcosts.
Every year, 350,000 patients contract bloodstream infections, causing over90,000 unnecessary deaths and significant costs to the healthcare system. Therapid identification of infecting pathogens is crucial to ensure early andappropriate therapy to save lives and reduce patient length-of-stay. Inresponse, AdvanDx leverages its molecular diagnostic products to detect andidentify infectious pathogens and provide therapy-directing results in hoursversus days.
AdvanDx's easy-to-use products employ standard lab techniques andequipment to reduce startup, implementation, technician and maintenance time,while providing fast results without sacrificing accuracy. Major medicalcenters, reference labs, government institutions and community hospitalsthroughout the United States, Europe and Asia rely on AdvanDx products,supported by a global network of service partners.For more information visit http://www.AdvanDx.com Company Contact: Joen T. Johansen Director of Marketing of AdvanDx +1-339-227-4052, firstname.lastname@example.org Media Inquiries: Joe Romano Partner of HighGround, Inc. +1-781-939-5800, Ext. 208 email@example.com